Rapid Stroke Diagnosis & Differentiation

  • Complements and enhances existing CT scanning ensuring fast and accurate diagnosis
  • Multiplex biochip for rapid stroke classification in under 30 minutes from a single plasma sample
  • Powered by Randox’s revolutionary, patented Biochip Technology using the Evidence MultiSTAT
  • Simple 2 step process from sample entry to results, offering efficient and accurate stroke classification and differentiation
  • Fast and accurate diagnostic classification between ischaemic and haemorrhagic stroke
  • Ensures better outcomes guaranteeing timely therapeutic intervention

The Randox Stroke Biochip is a rapid and highly sensitive blood test that will complement and enhance existing CT scanning technology to facilitate accurate classification of stroke patients and improve patient care pathways.

Using Randox revolutionary patented Biochips, the Randox Stroke Biochip provides a unique solution for simultaneous detection of multiple stroke biomarkers from a single sample, facilitating fast and accurate classification of stroke patients in an emergency setting.

Biomarkers Tested

  • GFAP
  • IL-6
  • FABP3
  • sTNFR1
  • D-Dimer
  • PARK 7
  • NDKA
  • GSTP1

Glial fibrillary acidic protein (GFAP) is a 432-residue protein predominantly expressed in astrocytes. It is distributed throughout the central nervous system. Type III intermediate filament (IF) protein is involved in cytoskeletal structure and function. It plays a role in numerous important CNS processes, including cell communication and the functioning of the blood brain barrier. GFAP is a biomarker candidate indicative of ICH in patients with symptoms of acute stroke. GFAP is released rapidly in the presence of expanding intracerebral bleeding, whereas a more gradual release occurs in ischaemic stroke.

Interleukin-6 (IL-6) may be used to help evaluate a person who has a condition associated with inflammation, including stroke. IL-6 is a cytokine, a protein produced by immune cells that acts on other cells to help regulate and/or promote an immune response. It also stimulates the production of acute phase reactants, proteins that increase in the blood with conditions that cause inflammation or tissue injury.

Fatty acid binding protein 3 (FABP3) is a 132-residue cytoplasmic protein. It is predominantly expressed in cardiac myocytes and diverse cell types throughout the body including the brain. FABP3 is involved in active fatty acid uptake, intracellular metabolism and/or transport of long-chain fatty acids.

Soluble Tumour Necrosis Factor Receptor 1 (sTNFR1) is a 207-residue secreted protein expressed in diverse cell types. Its primary role is to antagonise and buffer TNF alpha. High plasma levels of TNFr1 and TNFr2 have been associated with intracerebral hemorrhage (ICH), a type of intracranial bleed that occurs in the brain ventricles or tissue. High plasma levels are most clearly seen with ICH of nonlobar location, suggesting that tumour necrosis factor-mediated inflammation could be associated with vascular changes preceding ICH.

D-Dimer is a degradation product of fibrin, crosslinked by factor XIII during clot formation. Detection of this analyte reflects ongoing activation of the fibrinolytic pathway D-Dimer. Studies have suggested that higher D-Dimer levels are associated with higher risk of stroke, especially ischaemic stroke.

Parkinson Disease Protein 7 (PARK7) is a 189-residue protein, also referred to as deglycase DJ-1. It has a role in cell protection against oxidative stress and cell death and is activated following ischaemia and neuro-inflammatory insults.

Nucleoside Diphosphate Kinase A (NDKA) is a 152-residue protein that forms homo-hexameric complexes. It catalyses the exchange of terminal phosphate between different nucleoside di and triphosphates. NDKA is expressed in the brain and may occur in the circulation because of cerebral injury. It is associated with Alzheimer’s disease, Parkinson’s disease, Down Syndrome and Stroke.

Glutathione S-transferase, Pi (GSTP1) is a homodimeric 210 residue protein. It is a major enzyme involved in detoxification which protects cells exposed to oxidative stress and is a proposed marker of cerebral injury. GSTP1 has the potential to predict the time of stroke onset and may increase the number of patients accessing thrombolysis by complementing current guidelines for tissue plasminogen activator (tPA) which is an enzyme used for the treatment of stroke dissolving clots.

The Evidence MultiSTAT

Meet the Evidence MultiSTAT

The Evidence MultiSTAT is an easy to use, small footprint analyser facilitating on-site simultaneous detection of multiple stroke biomarkers.

Using chemiluminescence as a measurement principle, the Evidence MultiSTAT consistently delivers accurate results.

As minimal sample preparation is required, qualitative results are provided in less than 30 minutes offering efficient and accurate stroke classification.

MultiSTAT Cartridge

Meet the Cartridge

The Evidence MultiSTAT cartridge contains the reagents required for the chemiluminescent reaction to take place incorporated into its wells.

The process from sample entry to results can be completed in 2 simple steps, with minimal risk of human error.

No other components are required.